The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV)
the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 12 weeks after the end of treatment
Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus infection (HCV) in adults and children 3 years of age and older who meet specific requirements, as determined by a health care provider
HCV can be an opportunistic infection (OI) of HIV
It is also approved for use in human immunodeficiency virus (HIV)/HCV coinfection and patients with hepatocellular carcinoma awaiting liver transplantation who are within Milan criteria and have a Model
Date of approval Drug; On May 13th, 2011: Boceprevir was approved by the FDA for the treatment of chronic HCV to be used, in combination with peginterferon alfa and ribavirin, in adult patients
Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment May 25, 2023
SOF
(Gilead)
It is also the first approved regimen that does not require administration with interferon or ribavirin, two
Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) for the treatment of
Safety, metabolism and excretion of the drug are also emphasized